In the fourth and final part of this video interview, Vincent Keunen, founder & CEO of Andaman7 looks forward and highlights some potential advancements with the use of AI.
ACT: What are some patient-centric advancements you are looking forward to seeing in the next five years?
Keunen: The big thing today is clearly AI (artificial intelligence), right? Everybody's talking about it. There's probably too much talk, and there's a hype, obviously, like always, but it's also a real improvement. It really does help for some features. For example, what I’ve personally used AI for is to explain to me a document with information coming from a specialist doctor, and it has medical-specific terms—very hard to understand for patients, and so the AI can explain that in a simpler manner. AI can also summarize. For example, I put a whole document in for a checkup that I did one year ago, just a checkup on heart condition and there were two pages of information, and the AI summarized it by saying, “There is no problem, next checkup in one year,” which was perfect. Two sentences. It's just what I need in my case.
It can also help translate in different languages. That's important if you go abroad on vacation, or if you work abroad for some of the time. AI is clearly a big thing, and I think it will help a lot. Of course, there's all kinds of privacy questions and issues to solve, and quality issues also, all of that is important. Some things that we already know, like the mobile phone and the internet, they don't see innovations as much today, but they are pretty powerful technology for creating communities of patients to help them work together and to help the research industry. Maybe the three main things is mobile phone, internet, and AI put together—that will probably be a very interesting combination of technologies to help patients and then help providers and research also in their endeavor to help patients.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.